Share on StockTwits

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “market perform” rating reiterated by analysts at JMP Securities in a research report issued to clients and investors on Monday, American Banking News reports.

The analysts wrote, “Development of ALNY RNAi therapeutic candidates is progressing ahead of prior guidance; reiterate Market Outperform rating and $68 price target on Alnylam. Last Friday, ALNY announced key pipeline goals for 2014, including that the company now expects to exceed its original “Alnylam 5×15″ guidance from 2011. Previously, Alnylam had guided to have five genetic medicine programs in the clinic by the end of 2015, but now expects to end 2015 with six to seven genetic medicine programs in the clinic, including at least two programs in Phase III and five to six programs that will have achieved human proof-of-concept results supporting further development. We reiterate our Market Outperform rating and $68 PT based on DCF and SOTP valuation methodologies.”

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 40.89% during mid-day trading on Monday, hitting $93.28. 5,346,387 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 52-week low of $19.23 and a 52-week high of $67.97. The stock’s 50-day moving average is $62.47 and its 200-day moving average is $54.49. The company’s market cap is $5.917 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter last year, the company posted ($0.31) earnings per share. Alnylam Pharmaceuticals’s revenue was down 46.4% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals will post $-1.38 EPS for the current fiscal year.

A number of other firms have also recently commented on ALNY. Analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Thursday. They now have a $67.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $82.00 in a research note to investors on Monday, November 11th. They now have an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $63.43.

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.